As expected, a study has reported that treatment with a γ-secretase inhibitor, L-685,458, significantly reduced AD-like phenotypes such as memory dysfunction, defects of motor ability, and neuronal cell death in a Drosophila AD model that expresses both human APP and the β-secretase (BACE) gene [96]. This evidence concerns the gene BACE1 and Alzheimer disease.